Herceptin News and Research

RSS

Starving breast cancer cells of hedgehog significantly slows tumour growth and spread

While it is already known that breast cancer cells create the conditions for their own survival by communicating their needs to the healthy cells that surround them, Australian researchers have identified a new way of turning off that cellular cross talk.

4 Jun 2011

Researcher to evaluate new approach for treatment of triple-negative breast cancer

A multicenter clinical trial led by a researcher at the University of Maryland Marlene and Stewart Greenebaum Cancer Center will evaluate a new approach to treat triple-negative breast cancer, an often-aggressive type of cancer that is more common among African-Americans and young women.

4 Jun 2011

PTEN does not reduce effectiveness of breast cancer drug, Herceptin: Study

Contrary to what many oncologists had thought, a tumor suppressor protein known as PTEN does not reduce the effectiveness of the breast cancer drug Herceptin, according to a study by Mayo Clinic and North Central Cancer Research Group investigators.

4 Jun 2011

Two genes linked to worst cases of esophageal cancer

University of Rochester Medical Center researchers have pinpointed two genes that are amplified in the worst cases of esophageal cancer, providing data to support a new investigational treatment that targets those same genes.

19 May 2011

Study: 80% of U.S. physicians use Herceptin for HER2-positive metastatic gastric cancer treatment

In just over a month following the FDA's October 2010 approval of Roche's Herceptin for HER2-positive metastatic gastric cancer, more than 80 percent of U.S. physicians report using the drug, according to new research by GfK HealthCare.

18 May 2011

New avenue for treating breast cancer

Researchers at the CHUM Research Centre and the Peter MacCallum Cancer Centre in Australia have identified a new avenue for treating breast cancer.

17 May 2011

Rethink praises Ontario's decision to provide breast cancer patients with access to Herceptin

Today, Rethink Breast Cancer (Rethink) applauds the Ontario government's decision to provide breast cancer patients with tumours less than or equal to 1 cm access to the revolutionary drug Herceptin under the new Evidence Building Program.

13 May 2011

New approach links cancer cell metabolism with poor clinical outcome

Identifying gene mutations in cancer patients to predict clinical outcome has been the cornerstone of cancer research for nearly three decades, but now researchers at the Kimmel Cancer Center at Jefferson have invented a new approach that instead links cancer cell metabolism with poor clinical outcome. This approach can now be applied to virtually any type of human cancer cell.

15 Apr 2011

RXi Pharmaceuticals acquires Apthera

RXi Pharmaceuticals Corporation, a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies, today announced the completion of its previously announced acquisition of Apthera, Inc.

15 Apr 2011

Positive top-line results from Roche's T-DM1 Phase II trial in HER2-positive MBC

ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products, today announced that Roche has disclosed positive top-line results from the first randomized trial assessing trastuzumab emtansine in HER2-positive metastatic breast cancer.

7 Apr 2011

RXi Pharmaceuticals to acquire Apthera

RXi Pharmaceuticals Corporation, a recognized leader in RNAi-based therapeutic discovery and development, and Apthera, Inc., a private biotechnology company developing a pipeline of peptide-based immunotherapies for the adjuvant treatment of HER2-positive breast and other cancers, announced today the signing of a definitive merger agreement under which RXi will acquire Apthera.

31 Mar 2011

Multiple drugs bonded to 'transport vehicle' bypass healthy cells to attack breast cancer from inside

Researchers at Cedars-Sinai's Maxine Dunitz Neurosurgical Institute have employed a strategy using a mouse model to target important mechanisms inside the most challenging breast cancer cells. Earlier studies at Cedars-Sinai found a similar approach effective in attacking malignant brain tumor targets.

30 Mar 2011

Rethink acknowledges Ontario's new breast cancer program

Rethink Breast Cancer acknowledges today's swift decision by the Ontario government to take steps towards providing greater access to specific cancer treatments.

22 Mar 2011

Combination therapy may overcome Herceptin-resistant breast cancer

Breast cancer tumors take numerous paths to resist the targeted drug Herceptin, but a single roadblock at a crucial crossroads may restore a tumor's vulnerability to treatment, scientists at The University of Texas MD Anderson Cancer Center report on line at Nature Medicine.

14 Mar 2011

New analytic method suggests tumors grow in punctuated, staccato-like bursts

A new method of analyzing cancerous tumors developed by scientists at Cold Spring Harbor Laboratory suggests that tumors may not evolve gradually, but rather in punctuated or staccato-like bursts.

14 Mar 2011

Halozyme Therapeutics 2010 net loss decreases to $53.2 million

Halozyme Therapeutics, Inc., a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets, today reported financial results for the fourth quarter and year ended December 31, 2010.

11 Mar 2011

Multiple target therapy may treat HER2-positive breast cancers

Combining targeted therapies might be required for maximum anti-tumor activity when treating HER2-positive breast cancers, according to two new studies by Vanderbilt-Ingram Cancer Center investigators.

9 Mar 2011

Scientists uncover genetic pathway that affects breast cancer development

Using recent advances in genomics, researchers have uncovered a genetic pathway that affects the development of breast cancer, work that could help predict which patients are at risk of relapse for the disease.

3 Mar 2011

U-M scientists identify potential target to treat aggressive prostate cancer

Researchers at the University of Michigan Comprehensive Cancer Center have identified a potential target to treat an aggressive type of prostate cancer. The target, a gene called SPINK1, could be to prostate cancer what HER2 has become for breast cancer.

3 Mar 2011

Researchers discover new 'driver gene' in oestrogen receptor positive breast cancer

CANCER RESEARCH UK scientists have pinpointed a key cancer-causing gene that, when overactive, triggers a particularly aggressive type of breast cancer to develop.

18 Feb 2011

Herceptin News and Research

Starving breast cancer cells of hedgehog significantly slows tumour growth and spread

Researcher to evaluate new approach for treatment of triple-negative breast cancer

PTEN does not reduce effectiveness of breast cancer drug, Herceptin: Study

Two genes linked to worst cases of esophageal cancer

Study: 80% of U.S. physicians use Herceptin for HER2-positive metastatic gastric cancer treatment

New avenue for treating breast cancer

Rethink praises Ontario's decision to provide breast cancer patients with access to Herceptin

New approach links cancer cell metabolism with poor clinical outcome

RXi Pharmaceuticals acquires Apthera

Positive top-line results from Roche's T-DM1 Phase II trial in HER2-positive MBC

RXi Pharmaceuticals to acquire Apthera

Multiple drugs bonded to 'transport vehicle' bypass healthy cells to attack breast cancer from inside

Rethink acknowledges Ontario's new breast cancer program

Combination therapy may overcome Herceptin-resistant breast cancer

New analytic method suggests tumors grow in punctuated, staccato-like bursts

Halozyme Therapeutics 2010 net loss decreases to $53.2 million

Multiple target therapy may treat HER2-positive breast cancers

Scientists uncover genetic pathway that affects breast cancer development

U-M scientists identify potential target to treat aggressive prostate cancer

Researchers discover new 'driver gene' in oestrogen receptor positive breast cancer

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News